Subject:
- Active Substance: Preparation of live, attenuated varicella-zoster virus (Oka/Merck strain)
- Name: Zostavax®
- Therapeutic area: Treatment of Herpes Zoster
- Pharmaceutical company: MSD SHARP & DOHME GMBH
Time table:
- Publication of final assessment: 17.09.2013
Assessment information:
- Title: Zostavax for the prevention herpes zoster and postherpetic nostalgia
- Author/Co-Author: CVZ (Netherlands), UCSC Gemelli (Italy)
- Dedicated Reviewers: HAS (France), DPA/MoH Malta (Malta), RIZIV-INAMI (Belgium), BIQG/GÖG (Austria), MoH Czech (Czech Republic), Veneto/CRUF (Italy), DGFPS MSPSI (Spain)
G-BA assessment not available
Reason: First launch of Zostavax® was in 2006 (pre-AMNOG).